Literature DB >> 22967900

Progranulin compensates for blocked IGF-1 signaling to promote myotube hypertrophy in C2C12 myoblasts via the PI3K/Akt/mTOR pathway.

Shao-Yang Hu1, Chen-Chen Tai, Yen-Hsing Li, Jen-Leih Wu.   

Abstract

It is well known that growth hormone (GH)-induced IGF-1 signaling plays a dominant role in postnatal muscle growth. Our previous studies have identified a growth factor, progranulin (PGRN), that is co-induced with IGF-1 upon GH administration. This result prompted us to explore the function of PGRN and its association with IGF-1. In the present study, we demonstrated that, similar to IGF-1, PGRN can promote C2C12 myotube hypertrophy via the PI(3)K/Akt/mTOR pathway. Moreover, PGRN can rescue the muscle atrophy phenotypes in C2C12 myotube when IGF-1 signaling is blocked. This result shows that PGRN can substitute for IGF-1 signaling in the regulation of muscle growth. Our findings provide new insights into IGF-1-modulated complicated networks that regulate muscle growth.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22967900     DOI: 10.1016/j.febslet.2012.07.077

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

1.  PGRN induces impaired insulin sensitivity and defective autophagy in hepatic insulin resistance.

Authors:  Jiali Liu; Huixia Li; Bo Zhou; Lin Xu; Xiaomin Kang; Wei Yang; Shufang Wu; Hongzhi Sun
Journal:  Mol Endocrinol       Date:  2015-02-09

Review 2.  Skeletal muscle hypertrophy and regeneration: interplay between the myogenic regulatory factors (MRFs) and insulin-like growth factors (IGFs) pathways.

Authors:  Nadège Zanou; Philippe Gailly
Journal:  Cell Mol Life Sci       Date:  2013-04-04       Impact factor: 9.261

3.  Tumor necrosis factor receptor 2 may promote the proliferation and drug resistance of Kapras299 and L428 lymphoma cells via the AKT and WNT/β-catenin signaling pathways.

Authors:  Yanyan Liang; Yu Wang; Meng Xiao; Yunliang Hao; Yongtian Zhang; Shumei Li
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

4.  Progranulin Deficiency Reduces CDK4/6/pRb Activation and Survival of Human Neuroblastoma SH-SY5Y Cells.

Authors:  Ana de la Encarnación; Carolina Alquézar; Noemí Esteras; Ángeles Martín-Requero
Journal:  Mol Neurobiol       Date:  2014-11-07       Impact factor: 5.590

5.  Tumor necrosis factor receptor 2 promotes growth of colorectal cancer via the PI3K/AKT signaling pathway.

Authors:  Tao Zhao; Huihui Li; Zifeng Liu
Journal:  Oncol Lett       Date:  2016-11-21       Impact factor: 2.967

6.  In Vitro Effects of Emerging Bisphenols on Myocyte Differentiation and Insulin Responsiveness.

Authors:  Jiongjie Jing; Yong Pu; Almudena Veiga-Lopez; Lihua Lyu
Journal:  Toxicol Sci       Date:  2020-11-01       Impact factor: 4.849

Review 7.  The role of PGRN in musculoskeletal development and disease.

Authors:  Jessica Konopka; Brendon Richbourgh; Chuanju Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

Review 8.  Mechanisms of granulin deficiency: lessons from cellular and animal models.

Authors:  Gernot Kleinberger; Anja Capell; Christian Haass; Christine Van Broeckhoven
Journal:  Mol Neurobiol       Date:  2012-12-13       Impact factor: 5.590

9.  Integrative Analyses of miRNA-mRNA Interactions Reveal let-7b, miR-128 and MAPK Pathway Involvement in Muscle Mass Loss in Sex-Linked Dwarf Chickens.

Authors:  Wen Luo; Shumao Lin; Guihuan Li; Qinghua Nie; Xiquan Zhang
Journal:  Int J Mol Sci       Date:  2016-02-24       Impact factor: 5.923

10.  Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia.

Authors:  Christopher J Holler; Georgia Taylor; Zachary T McEachin; Qiudong Deng; William J Watkins; Kathryn Hudson; Charles A Easley; William T Hu; Chadwick M Hales; Wilfried Rossoll; Gary J Bassell; Thomas Kukar
Journal:  Mol Neurodegener       Date:  2016-06-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.